Back to Search
Start Over
Contribution of survivin to the immune system, allergies and autoimmune diseases.
- Source :
-
Human immunology [Hum Immunol] 2023 Apr; Vol. 84 (4), pp. 301-310. Date of Electronic Publication: 2023 Feb 06. - Publication Year :
- 2023
-
Abstract
- In addition to malignancies, survivin (a member of the apoptosis inhibitor family) has been implicated in the pathogenesis of inflammatory disorders, including autoimmune and allergic diseases. Survivin is constantly expressed in the proliferating hematopoietic progenitor cells, and it is re-expressed in the mature cells of the innate and adaptive immunity, upon activation. Survivin enhances the expression of co-stimulatory molecules and MHC class II molecules in dendritic cells, and promotes the lifespan of macrophages, neutrophils, and eosinophils, while suppressing natural killer (NK) cell activity. Survivin has been implicated in T cell maturation, T cell expansion, effector CD4 <superscript>+</superscript> T cell differentiation, maintenance of memory CD4 <superscript>+</superscript> T and CD8 <superscript>+</superscript> T cells, as well as antibody production. Upregulated expression of survivin was indicated in the T cells as well as various samples collected from allergic patients. Survivin can contribute to the pathogenesis of allergic diseases via the promotion of the Th2 polarization, promoting IL-4 expression, compromising activation-induced cell death (AICD) in Th2 cells, and preventing apoptosis of eosinophils, as well as, amplification of eosinophilia. Moreover, survivin can interfere with clonal deletion of autoreactive T and B cells, as well as suppress Treg cell development and activity supporting the development of autoimmune diseases. This review discusses the role of survivin in immunity, allergy and autoimmunity as well as provides evidence that survivin may be considered as a novel therapeutic target for the treatment of allergic and autoimmune diseases.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1879-1166
- Volume :
- 84
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Human immunology
- Publication Type :
- Academic Journal
- Accession number :
- 36754653
- Full Text :
- https://doi.org/10.1016/j.humimm.2023.01.009